WO2003061694A1 - Immunosuppression de la reponse immune humorale par des anticorps anti-cd20 - Google Patents

Immunosuppression de la reponse immune humorale par des anticorps anti-cd20 Download PDF

Info

Publication number
WO2003061694A1
WO2003061694A1 PCT/US2002/014600 US0214600W WO03061694A1 WO 2003061694 A1 WO2003061694 A1 WO 2003061694A1 US 0214600 W US0214600 W US 0214600W WO 03061694 A1 WO03061694 A1 WO 03061694A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
toxin
cells
patient
administration
Prior art date
Application number
PCT/US2002/014600
Other languages
English (en)
Inventor
Amy P. Sing
Clay B. Siegall
Original Assignee
Seattle Genetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics, Inc. filed Critical Seattle Genetics, Inc.
Publication of WO2003061694A1 publication Critical patent/WO2003061694A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Definitions

  • the present invention relates to methods for reducing or preventing the production of endogenous antibodies to an immunogenic molecule that is administered as a therapeutic agent or a component of a therapeutic composition, thereby minimizing unwanted side effects to administration of the immunogenic molecule and maximizing its efficacy as a therapeutic or the efficacy of a therapeutic associated with it.
  • Said methods entail the depletion of antibody-producing B-cells in the patient by administering an anti- CD20 antibody prior to, concurrently with or after administration of the immunogenic molecule to the patient.
  • the immune system of vertebrates (for example, primates, which include humans, apes, monkeys, etc.) consists of a number of organs and cell types (lymphocytes) which have evolved to accurately and specifically recognize antigens, for example proteins of foreign microorganisms which invade the vertebrate-host, specifically bind to such foreign antigens and eliminate/destroy such foreign microorganisms.
  • B-cells are a type of lymphocyte responsible for antibody production (humoral immunity). Each B cell within the host expresses a different antibody on its surface-thus, one B cell will express an antibody specific for one antigen, while another B cell will express an antibody specific for a different antigen.
  • B-cells are quite diverse, and this diversity is critical to the immune system.
  • each B cell can produce 10 7 to 10 8 antibody molecules.
  • B cells which express a particular antibody multiply by clonal expansion.
  • cytokines When stimulated by cytokines, B-cells differentiate into plasma cells, which have a surplus of protein-producing endoplasmic reticulum (ER).
  • ER endoplasmic reticulum
  • the plasma cells have a short life cycle, and die when the foreign antigen has been neutralized.
  • the responding B-cell population is subsequently reduced to its normal size apart from a few cells remaining as memory cells.
  • Antibodies or immunoglobulins (Ig) are proteins composed of heavy chains and light chains, each of which contains a constant region and a variable region.
  • Antibodies bind specifically to antigens and form a complex, which may cause agglutination and precipitation, mask the active sites of the antigens thereby neutralizing its activity, or activate the complement cascade.
  • a single Ig complexed with its antigen can activate a complement cascade with mobilization of up to 10 9 new complement molecules carrying enzymes that rapidly lyse antigen-carrying cells.
  • the most abundant antibody subtype is IgG, which has a high antigen affinity and is the antibody of the secondary response to protein antigens (e.g., viruses and toxins).
  • B-cells express cell surface proteins which can be utilized as "markers" for differentiation and identification.
  • CD20 human B lymphocyte-restricted differentiation antigen CD20 (also known as Bl or Bp35).
  • CD20 is initially expressed during early pre-B cell development and remains until plasma cell (antibody-producing cell) differentiation.
  • the CD20 molecule may regulate a step in the activation process which is required for cell cycle initiation and differentiation.
  • the humoral immune response which is beneficial for preventing infectious diseases by neutralizing the disease agents, has been a limiting factor in the development of various protein therapeutics due to the neutralization of therapeutic proteins by antibodies.
  • the efficacy for immunotoxins as therapeutic agents has been severely hampered by the humoral immune response.
  • One of the main obstacles to overcome with regard to immunotoxins is the immunogenicity of the toxin component.
  • a summary of 15 clinical trials with immunotoxins in which antibody induction was studied determined that in 12 (80%) of the trials, at least 50% of patients developed antibodies against the immunotoxin being evaluated (Nitetta, et al, 1993, Immunology Today 14:252-259). In four of the clinical trials more than 90% of the patients developed antibodies.
  • Immunotoxin treatment needs to be given repeatedly in order to maximize tumor regression and eradication (Friedman, et al, 1993, 150:3054-61; Skolnick, JAMA 270:2280; and Wawrzynczak, 1991, Br. J. Cancer 64:624-630).
  • endogenous antibody formation occurs, the efficacy of immunotoxin treatment is substantially diminished or negated. This decreased efficacy is thought to result from the increased rate of clearance of the immunotoxin or from blocking of the receptor site or toxic activity site of the immunotoxin (Nitetta, et al, 1993, Today 14:252-259; and Wawrzynczak, and
  • Immunosuppressive drugs such as cyclophosphamide, prednisone, azathioprine and cyclosporin A failed to prevent patients from developing endogenous antibody in the face of repeated administration of immunotoxin (Wawrzynczak, 1991, Br. J. Cancer 64:624-630).
  • CTLA4 Ig One immunosuppressive agent, CTLA4 Ig, when co-administered with an immunotoxin, inhibited the production of antibodies against the toxin in rodents and dogs; however, this reagent has not been approved for human use and thus not tested for its efficacy in reducing the humoral response to immunotoxins in humans (Siegall et al, 1997, J. Immunol. 159(10 ⁇ :5168-731
  • the present invention provides methods for reduction or prevention of an immune response to an immunogenic molecule in a patient, with the proviso that the immunogenic molecule is not a component of a tissue transplant or an autoantigen, comprising administering to a patient an anti-CD20 monoclonal antibody in an amount sufficient to deplete the patient's circulating B-cells, wherein said anti-CD20 monoclonal antibody is administered to the patient prior to, concurrently with or after the immunogenic molecule is administered to the patient.
  • the immunogenic molecule is a therapeutic molecule.
  • the immunogenic molecule is an immunotoxin.
  • the immunogenic molecule is a fusion protein.
  • the fusion protein comprises a toxin.
  • the fusion protein comprises an enzyme such as a pro-drug converting enzyme.
  • the therapeutic composition comprises a gene therapy vector.
  • the anti-CD20 monoclonal antibody is a chimeric antibody. In one embodiment, the chimeric anti-CD20 antibody is chimeric 2B8 antibody. In another embodiment, the chimeric anti-CD20 antibody is chimeric Bl antibody. In another embodiment, the anti-CD20 monoclonal antibody is a humanized antibody. In yet another embodiment, the anti-CD20 monoclonal antibody is a human antibody.
  • the amount of anti-CD20 antibody administered is sufficient to deplete the patient's circulating B-cells by at least 25%, by at least 35%, by at least 50%, by at least 60%, by at least 75%, by at least 85%, or by at least 90%o.
  • said depletion is achieved prior to the administration of the immunogenic molecule to the patient.
  • the immunogenic molecule is administered to the patient as a therapeutic or as a component of a therapeutic composition.
  • the anti-CD20 antibody is administered concurrently with the immunogenic molecule.
  • the anti-CD20 antibody is administered prior to administration of the immunogenic molecule.
  • the immunogenic molecule is administered within two weeks of administration of the anti- CD20 antibody.
  • the immunogenic molecule is administered within ten days of administration of the anti-CD20 antibody.
  • the immunogenic molecule is administered within one week of administration of the anti-CD20 antibody.
  • the immunogenic molecule is administered within five days of administration of the anti-CD20 antibody.
  • the immunogenic molecule is administered within three or two days of administration of the anti-CD20 antibody.
  • FIG. 1 Inhibition of protein synthesis in L2987 human carcinoma cells by serum samples of patients receiving BR96 sFv-PE40 is reduced by the present human antitoxin antibody (HAT A) present in the serum.
  • the X axis shows the dilution of each serum sample (D corresponds to a sample with a HATA titer of 1 :21,870; ⁇ corresponds to a sample with a HATA titer of 1 :590,490; and x corresponds to a sample with a HATA titer of 1 :90) or the BR96 sFv-PE40 control ( ⁇ ).
  • the X axis shows the dilution of the serum and the Y axis shows the percentage inhibition of protein synthesis relative to untreated L2987 human carcinoma cells.
  • the data indicate that neutralization of BR96 sFv-PE40 activity by HATA reduces its toxicity and therefore its inhibition of protein synthesis in the L2987 cell line relative to the BR96 sFv-PE40 control. The extent of neutralization correlates with the HATA titer.
  • the present invention provides methods and compositions for using anti- CD20 monoclonal antibodies to limit or prevent an immune response to an immunogenic molecule in a patient, with the proviso that the immunogenic molecule is not a component of a tissue transplant or an autoantigen.
  • the immunogenic molecule can be a monoclonal antibody, a toxin, a pro-drug, an enzyme, a gene therapy vector, or a combination of the foregoing.
  • the present invention encompasses the use of anti-CD20 antibodies to deplete a patient's peripheral B lymphocyte population, so that a therapeutic agent can be administered to the patient without eliciting an immune response against the therapeutic that would compromise its efficacy.
  • the anti-CD20 antibody comprises the variable region or the CDRs of monoclonal antibody 2B8.
  • the anti-CD20 antibody is chimeric 2B8 antibody ("C2B8").
  • C2B8 is commercially available as RITUXAN®, and has been approved by the FDA for the treatment of patients with relapsed or refractory, low grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma (NHL).
  • C2B8 is an IgGl ⁇ inimunoglobulin with murine light- and heavy-chain variable region sequences.
  • C2B8 comprises 2 heavy chains of 451 amino acids each and two light chains of 213 amino acids each, with a total molecular mass of 145kD.
  • ADCC antibody-dependent cellular cytotoxicity
  • CDC complement-dependent cytotoxicity
  • apoptosis programmeed cell death
  • the C2B8 antibody is glycosylated with bisected oligosaccharides.
  • the anti-CD20 antibody comprises the variable region or the CDRs of one or more of the following anti-CD20 monoclonal antibodies: FBI, 1F5, 2H7, 93-1B3, 109-3C2, Bl, B9E9, 7D1, H147, L26, L27, and MEM-97.
  • anti-CD20 monoclonal antibodies FBI, 1F5, 2H7, 93-1B3, 109-3C2, Bl, B9E9, 7D1, H147, L26, L27, and MEM-97.
  • Many of these anti-CD20 antibodies have been administered to humans in clinical trials and been deemed safe for human use.
  • radio-iodinated Bl has been used in the treatment of B-cell lymphoma (see, e.g., Kaminski et al, 1993, New Eng. J. Med.
  • anti-CD20 antibodies are available commercially, either as the purified monoclonal antibody or the antibody-secreting hybridoma.
  • Sources of the anti- CD20 antibodies or hybridomas include Lab Vision Corporation, Fremont, CA (93-1B3 antibody); Bioprobe BV, the Netherlands (B9E9, 93-1B3 and 109-3C2 hybridomas); Serotec, United Kingdom (2H7, 7D1 and H147 antibodies); ID Labs, Ontario, Canada (2H7 antibody); Ancell, Bayport, Minnesota (2H7 antibody); the American Type Culture Collection, Manassas, Virginia (chimeric 2H7-expressing cell line C273; 1F5 hybridoma). Further, the sequence of some of the anti-CD20 antibodies is known.
  • MEM- 97 has been partially sequenced (Dubel et al, 1994, J. Immunol. Methods 175:89-95).
  • a comparison of the variable regions of the light and heavy chains of the anti-CD20 antibodies C2B8, B9E9, and 1F5 is provided in Fig. 1 of Schultz et al, 2000, Cancer Research 60:6663-6669.
  • the anti-CD20 antibodies of the invention are preferably monoclonal, and may be multispecific, human, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a Fab expression library, and
  • antibody refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecif ⁇ cally binds CD20.
  • the immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgGl, IgG2, IgG3, IgG4, IgAl and IgA2) or subclass of immunoglobulin molecule.
  • CD20- human antigen-binding antibody fragments can be used to deplete a patient's B-cells and include, but are not limited to, Fab, Fab' and F(ab') 2 , Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a V L or N H domain.
  • Antigen- binding antibody fragments, including single-chain antibodies may comprise the CD20- binding variable region(s) alone or in combination with the entirety or a portion of the following: hinge region, CHI, CH2, CH3 and CL domains.
  • variable regions are derived human, murine (e.g., mouse and rat), donkey, sheep, rabbit, goat, guinea pig, camelid, horse, or chicken antibodies.
  • murine antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries, from human B-cells, or from animals transgenic for one or more human immunoglobulin, as described infra and, for example in U.S. Patent ⁇ o.5,939,598 by Kucherlapati et al.
  • the anti-CD20 antibodies that may be used in the methods of the present invention may be monospecific, bispecific, trispecific or of greater multispecificity.
  • Multispecific antibodies may be specific for different epitopes of CD20 or may be specific for both CD20 as well as for a heterologous protein. See, e.g. , PCT publications WO 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, et al, 1991, J. Immunol. 147:60-69; U.S. Patent Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920; 5,601,819; Kostelny et al, 1992, J. Immunol. 148:1547-1553.
  • Antibodies of the present invention may be described or specified in terms of
  • antibodies of the invention comprise one or more CDRs of the anti-CD20 antibodies 2B8, FBI, 1F5, 2H7, 93-1B3, 109-3C2, Bl, B9E9, 7D1, H147, L26, L27, and MEM-97.
  • those antibodies comprise human constant regions.
  • those antibodies comprise human constant and framework regions.
  • anti-CD20 antibodies for use in the methods of the present invention may also be described or specified in terms of their primary structures.
  • the present invention further encompasses the use of an anti-CD20 antibody that has amino acid substitutions relative to a native anti-CD20 antibody that resulting in
  • An exemplary method for identifying anti-CD20 antibodies with increased affinity is through systematic mutagenesis and screening, preferably reiterative screening, for antibodies with improved affinity to CD20, for example as described by Wu et al, 1998, Proc. Natl. Acad. Sci. U.S.A. 95:6037-6042.
  • Anti-CD20 antibodies useful in the methods of the present invention may also be described or specified in terms of their binding affinity to CD20.
  • Preferred binding affinities include those with a dissociation constant or Kd less than 5 X 10 "2 M, 10 "2 M, 5 X 10 "3 M, 10 “3 M, 5 X 10- 4 M, 10 "4 M, 5 X 10 "5 M, 10 “5 M, 5 X 10 "6 M, 10 “6 M, 5 X 10 "7 M, 10 “7 M, 5 X 10 “8 M, 10 “8 M, 5 X 10 "9 M, 10 "9 M, 5 X 10 "10 M, 10 "10 M, 5 X 10 "11 M, 10 '11 M, 5 X
  • anti-CD20 antibodies useful in the methods of the invention include derivatives that are modified, i.e, by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from binding to CD20 or from depleting B-cells.
  • the antibody i.e, by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from binding to CD20 or from depleting B-cells.
  • the antibody include derivatives that are modified, i.e, by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from binding to CD20 or from depleting B-cells.
  • the antibody include derivatives that are modified, i.e, by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from binding to CD20 or from depleting B-cells.
  • the antibody i.e, by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody
  • 35 derivatives include antibodies that have been modified, e.g. , by glycosylation, acetylation, pegylation, phosphylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications may be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.
  • the anti-CD20 antibodies useful in the methods of the present invention may be generated by any suitable method known in the art.
  • Polyclonal antibodies to CD20 can be produced by various procedures well known in the art.
  • CD20 can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc. to induce the production of sera containing polyclonal antibodies specific for the protein.
  • adjuvants may be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette- Guerin) and corynebacterium parvum. Such adjuvants are also well known in the art.
  • Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof.
  • monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al, Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed., 1988); Hammerling, et al, in: Monoclonal Antibodies and T-Cell Hybridomas 563-681 (Elsevier, N.Y., 1981) (said references incorporated by reference in their entireties).
  • the term “monoclonal antibody” as used herein is not limited to antibodies produced through hybridoma technology.
  • the term “monoclonal antibody” refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced
  • mice can be immunized with CD20 or a cell expressing CD20 or a fragment or derivative thereof.
  • an immune response e.g., antibodies specific for CD20 are detected in the mouse serum
  • the mouse spleen is harvested and splenocytes isolated.
  • the splenocytes are then fused by well known techniques to any suitable myeloma cells, for example cells from cell line SP20 available from the ATCC.
  • Hybridomas are selected and cloned by limited dilution.
  • the hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding CD20.
  • Ascites fluid which generally contains high levels of antibodies, can be generated by injecting mice with positive hybridoma clones.
  • Antibody fragments which recognize specific epitopes may be generated by known techniques.
  • Fab and F(ab') 2 fragments of the invention may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab') 2 fragments).
  • F(ab') 2 fragments contain the variable region, the light chain constant region and the CH 1 domain of the heavy chain.
  • the anti-CD20 antibodies useful in the methods of the present invention can also be generated using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the nucleic acid sequences encoding them.
  • such phage can be utilized to display antigen binding domains expressed from a repertoire or combinatorial antibody library (e.g. , human or murine).
  • a repertoire or combinatorial antibody library e.g. , human or murine
  • functional antibody domains are displayed on the surface of phage particles which carry the nucleic acid sequences encoding them.
  • DNA sequences encoding V H and V L domains are amplified from animal cDNA libraries (e.g., human or murine cDNA libraries of lymphoid tissues). The DNA encoding the V H and V L domains are recombined together with an scFv linker by PCR and cloned into a phagemid vector (e.g.
  • the vector is electroporated in E. coli and the E. coli is infected with helper phage.
  • Phage used in these methods are typically filamentous phage including fd and M13 binding domains expressed from phage with Fab, Fv or disulfide stabilized Fv antibody domains recombinantly fused to either the phage gene III or gene VIII protein.
  • Phage expressing an antigen binding domain that binds to CD20 can be selected or identified with antigen e.g., using labeled antigen or antigen bound or captured to a solid surface or bead.
  • the antibody coding regions from the phage can be isolated and used to generate whole antibodies
  • a chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a
  • framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding.
  • Antibodies can be humanized using a variety of techniques
  • Human antibodies can be made by a variety of methods known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See also, U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645, WO 98/50433, WO 98/24893, WO 98/16654, WO 96/34096, WO 96/33735, and WO 91/10741; each of which is incorporated herein by reference in its entirety.
  • Human antibodies can also be produced using transgenic mice which express human immunoglobulin genes.
  • the human heavy and light chain immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells.
  • the mouse heavy and light chain immunoglobulin genes may be rendered non-functional separately or simultaneously with the introduction of human immunoglobulin loci by homologous recombination.
  • homozygous deletion of the JH region prevents endogenous antibody production.
  • the modified embryonic stem cells are expanded and microinjected into blastocysts to produce chimeric mice.
  • the chimeric mice are then bred to produce homozygous offspring which express human antibodies.
  • the transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of CD20.
  • Monoclonal antibodies directed against the antigen can be obtained from the immunized, transgenic mice using conventional hybridoma technology.
  • the human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation.
  • IgG, IgA, IgM and IgE antibodies For an overview of this technology for producing human antibodies, .see, Lonberg and Huszar, 1995, Int. Rev. Immunol. 13:65-93.
  • Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection.”
  • a selected non-human monoclonal antibody e.g. , a mouse antibody
  • is used to guide the selection of a completely human antibody recognizing the same epitope Jespers et al, 1994,
  • antibodies to CD20 can, in turn, be utilized to generate anti-idiotype antibodies that "mimic" CD20 using techniques well known to those skilled in the art. (See, 0 e.g., Greenspan & Bona, 1989, FASEB J. 7(5):437-444; and Nissinoff, 1991, J. Immunol.
  • Fab fragments of such anti-idiotypes can be used in therapeutic regimens to elicit an individual's own immune response against CD20 and B-cells.
  • anti-CD20 antibodies useful in the methods of the invention may further be recombinantly fused to a heterologous protein at the N- or C-terminus or chemically 5 conjugated (including covalently and non-covalently conjugations) to cytotoxic agents, proteins or other compositions.
  • the molecules are identical at that position.
  • the determination of percent identity between two sequences can be accomplished using a mathematical algorithm.
  • a preferred, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of 5 Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. USA 87:2264-2268, modified as in Karlin and Altschul, 1993, Proc. Natl. Acad. Sci. USA 90:5873-5877.
  • Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul, et al, 1990, J. Mol. Biol. 215:403-410.
  • BLAST protein searches can be
  • Gapped BLAST can be utilized as described in Altschul et al., 1997, Nucleic Acids Res. 25:3389-3402.
  • PSI-Blast can be used to perform an iterated search which detects distant relationships between molecules (Id.).
  • protein sequence alignment may be carried out using the CLUSTAL W algorithm, as described by Higgins et al, 1996, Methods Enzymol. 266:383-
  • the percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, only exact matches are counted.
  • a putative anti-CD20 antibody may be assayed for immunospecific binding to CD20 by any method known in the art.
  • the immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as Western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich” immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few.
  • hnmunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate at pH 7.2, 1% Trasylol) supplemented with protein phosphatase and/or protease inhibitors (e.g., EDTA, PMSF, aprotinin, sodium vanadate), adding the antibody to the cell lysate, incubating for a period of time (e.g., 1-4 hours) at 40° C, adding protein A and/or protein G sepharose beads to the cell lysate, incubating for about an hour or more at 40° C, washing the beads in lysis buffer and resuspending the beads in SDS/sample buffer.
  • a lysis buffer such as RIPA buffer (1% NP-40 or Triton X-100, 1% sodium
  • the ability of the antibody to immunoprecipitate CD20 can be assessed by, e.g., Western blot analysis.
  • One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the binding of the antibody to CD20 and decrease the background (e.g., pre-clearing the cell lysate with sepharose beads).
  • immunoprecipitation protocols see, e.g., Ausubel et al, eds., 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.16.1.
  • Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%- 20% SDS-PAGE depending on the molecular weight of the antigen), transferring the protein sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, incubating the membrane in blocking solution (e.g., PBS with 3% BSA or non-fat milk), washing the membrane in washing buffer (e.g., PBS-Tween 20), blocking the membrane with primary antibody (i. e.
  • a polyacrylamide gel e.g., 8%- 20% SDS-PAGE depending on the molecular weight of the antigen
  • a membrane such as nitrocellulose, PVDF or nylon
  • blocking solution e.g., PBS with 3% BSA or non-fat milk
  • washing buffer e.g., PBS-Tween 20
  • primary antibody i. e.
  • the putative anti-CD20 antibody diluted in blocking buffer, washing the membrane in washing buffer, incubating the membrane with a secondary antibody (which recognizes the primary antibody, e.g., an anti-human antibody) conjugated to an enzyme substrate (e.g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e.g., 32 P or 125 I) diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the secondary antibody.
  • an enzyme substrate e.g., horseradish peroxidase or alkaline phosphatase
  • radioactive molecule e.g., 32 P or 125 I
  • ELISAs comprise preparing antigen (i. e. , CD20), coating the well of a 96 well microtiter plate with the CD20, adding the antibody conjugated to a detectable compound such as an enzyme (e.g., horseradish peroxidase or alkaline phosphatase) to the well and incubating for a period of time, and detecting the presence of the antibody.
  • a detectable compound such as an enzyme (e.g., horseradish peroxidase or alkaline phosphatase)
  • the antibody does not have to be conjugated to a detectable compound; instead, a second antibody (which recognizes the antibody of interest) conjugated to a detectable compound may be added to the well. Further, instead of coating the well with the antigen, the antibody may be coated to the well. In this case, a second antibody conjugated to a detectable compound may be added following the addition of CD20 protein to the coated well.
  • a second antibody conjugated to a detectable compound may be added following the addition of CD20 protein to the coated well.
  • the binding affinity of an antibody to CD20 and the off-rate of an antibody CD20 interaction can be determined by competitive binding assays.
  • a competitive binding assay is a radioimmunoassay comprising the incubation of labeled CD20 (e.g., 3 H or 125 I) with the antibody of interest in the presence of increasing amounts of unlabeled CD20, and the detection of the antibody bound to the labeled CD20.
  • the affinity of the antibody for CD20 and the binding off-rates can then be determined from the data by Scatchard plot analysis. Competition with a second antibody can also be determined using radioimmunoassays.
  • CD20 is incubated with the antibody of interest conjugated to a labeled compound (e.g., 3 H or 125 I) in the presence of increasing amounts of an unlabeled second antibody.
  • a labeled compound e.g., 3 H or 125 I
  • the proteins, including antibodies, of the invention can be produced by any method known in the art for the synthesis of proteins, in particular, by chemical synthesis or preferably, by recombinant expression techniques.
  • Recombinant expression of an anti-CD20 antibody requires construction of an expression vector containing a nucleic acid that encodes the anti-CD20 antibody. Once a nucleic acid encoding an anti-CD20 antibody has been obtained, the vector for the production of the anti-CD20 antibody may be produced by recombinant DNA technology using techniques well known in the art.
  • an anti- CD20 antibody by expressing a nucleic acid containing a nucleotide sequence encoding said anti-CD20 antibody are described herein.
  • Methods which are well known to those skilled in the art can be used to construct expression vectors containing coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination.
  • the invention thus, provides replicable vectors comprising a nucleotide sequence encoding an anti-CD20 antibody operably linked to a promoter.
  • the anti-CD20 antibody nucleotide sequence may encode a heavy or light chain thereof, or a heavy or light chain variable domain, operably linked to a promoter.
  • Such vectors may include the nucleotide sequence encoding the constant region of the anti-CD20 antibody molecule (see, e.g., PCT Publication WO 86/05807; PCT Publication WO 89/01036; and U.S. Patent No. 5,122,464) and the variable domain of the anti-CD20 antibody may be cloned into such a vector for expression of the entire heavy or light chain.
  • the expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce a protein of the invention.
  • the invention encompasses host cells containing a nucleic acid encoding a protein of the invention, operably linked to a heterologous promoter.
  • vectors encoding both the heavy and light chains may be co-expressed in the host cell for expression of the entire immunoglobulin molecule, as detailed below.
  • host-expression vector systems may be utilized to express the protein molecules of the invention.
  • Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, express a protein of the invention in situ.
  • These include but are not limited to microorganisms such as bacteria (e.g., E. coli, B.
  • subtilis transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., Saccharomyces, Pichia) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculo virus) containing antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mamm
  • bacterial cells such as Escherichia coli, and more preferably, eukaryotic cells, especially for the expression of whole recombinant antibody molecules, are used for the expression of a recombinant protein of the invention.
  • mammalian cells such as Chinese hamster ovary cells (CHO)
  • CHO Chinese hamster ovary cells
  • a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for proteins of the invention (Foecking et al, 1986, Gene 45:101; Cockett et al, 1990, Bio/Technology 8:2).
  • a number of expression vectors may be advantageously selected depending upon the use intended for the folding and post-translation modification requirements protein being expressed.
  • vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable.
  • vectors include, but are not limited, to the E. coli expression vector pUR278 (Ruther et al, 1983, ⁇ MBO 1. 2:1791), in which the anti-CD20 antibody coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, 1985, Nucleic Acids Res. 13:3101-3109; Van Heeke & Schuster, 1989, J.
  • pG ⁇ X vectors may also be used to express fusion proteins with glutathione S- transferase (GST).
  • GST glutathione S- transferase
  • fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to matrix glutathioneagarose beads followed by elution in the presence of free glutathione.
  • the pG ⁇ X vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned anti-CD20 antibody can be released from the GST moiety.
  • Autographa californica nuclear polyhedrosis virus (AcNPN) is used as a vector to express foreign genes.
  • the virus grows in Spodoptera frugiperda cells.
  • the anti-CD20 antibody coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an Ac ⁇ PN promoter (for example the polyhedrin promoter).
  • a number of viral-based expression systems may be utilized.
  • the coding sequence of the anti-CD20 antibody may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence.
  • This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non- essential region of the viral genome (e.g., region El or E3) will result in a recombinant virus that is viable and capable of expressing the anti-CD20 antibody in infected hosts.
  • Specific initiation signals may also be required for efficient translation of inserted coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see, Bittner et al, 1987, Methods in Enzymol. 153:51-5441
  • a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of anti- CD20 antibodies may be important for the binding and/or activities of the antibodies.
  • Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the anti-CD20 antibody expressed.
  • eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used.
  • Such mammalian host cells include but are not limited to CHO, NERO, BHK, Hela, COS, MDCK, 293, 3T3, and W138.
  • stable expression is preferred.
  • cell lines which stably express an anti-CD20 antibody may be engineered.
  • host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media.
  • the selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines.
  • This method may advantageously be used to engineer cell lines which express an anti-CD20 antibody for use in the methods of the present invention.
  • a number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al, 1977, Cell 11:223), hypoxanthine- guanine phosphoribosyltransferase (Szybalska & Szybalski, 1992, Proc. Natl. Acad. Sci. USA 48:202), and adenine phosphoribosyltransferase (Lowy et al, 1980, Cell 22:8-17) genes can be employed in fk-, hgprt- or aprt- cells, respectively.
  • antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al, 1980, Proc. Natl. Acad. Sci. USA 77:357; O ⁇ are et al, 1981, Proc. Natl. Acad. Sci. USA 78:1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, Proc. Natl. Acad. Sci.
  • an anti-CD20 antibody can be increased by vector amplification (for a review, see Bebbington and Hentschel, "The Use of Vectors Based on Gene Amplification for the Expression of Cloned Genes in Mammalian Cells in DNY Cloning", Vol.3. (Academic Press, New York, 1987)).
  • vector amplification for a review, see Bebbington and Hentschel, "The Use of Vectors Based on Gene Amplification for the Expression of Cloned Genes in Mammalian Cells in DNY Cloning", Vol.3. (Academic Press, New York, 1987)
  • a marker in the vector system expressing the anti-CD20 antibody is amplifiable, increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene. Since the
  • the host cell may be co-transfected with two expression vectors encoding an anti-CD20 antibody, the first vector encoding a heavy chain derived protein and the second vector encoding a light chain derived protein.
  • the two expression vectors encoding an anti-CD20 antibody, the first vector encoding a heavy chain derived protein and the second vector encoding a light chain derived protein.
  • 10 vectors may contain identical selectable markers which enable equal expression of heavy and light chain proteins.
  • a single vector may be used which encodes, and is capable of expressing, both heavy and light chain proteins.
  • the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, 1986, Nature 322:52 (1986); Kohler, 1980, Proc. Natl. Acad. Sci. USA 77:2
  • the coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.
  • an anti-CD20 antibody may be purified by any method known in the art for purification of proteins, for example, by chromatography (e.g., ion exchange; affinity,
  • affinity for the specific antigen i. e. , CD20
  • Protein A or affinity for a heterologous fusion partner wherein the protein is a fusion protein
  • sizing column chromatography centrifugation, differential solubility, or by any other standard technique for the purification of proteins.
  • the present invention encompasses the use of anti-CD20 antibodies
  • heterologous proteins of preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or at least 100 amino acids.
  • the fusion does not necessarily need to be direct, but may occur through linker sequences.
  • the present invention provides methods for reduction or prevention of an immune response to an immunogenic molecule in a patient by administering to the patient an anti-CD20 monoclonal antibody in an amount sufficient to deplete the patient's circulating B-cells.
  • the immunogenic molecule is a toxin, i.e., a cytostatic or cytocidal agent.
  • the toxin is preferably covalently linked to a second protein in which the toxin's fusion partner targets the toxin to a particular cell type.
  • the covalent linkage can be by way of conjugation or, more preferably, by way of recombinant expression as a fusion protein in which the toxin is translated in frame at the - or C-terminus of the second protein.
  • Chimeric toxins, recombinant toxins, and immunotoxins are a relatively new group of macromolecules that are being developed for use in a variety of human illnesses.
  • the underlying therapeutic principle is the joining of a toxin molecule to a targeting molecule of high specificity. The targeting molecule then delivers the toxin to the unwanted cell or tissue, where the toxin portion of the molecule is internalized and poisons the cell.
  • Chimeric toxins, recombinant toxins, and immunotoxins are potentially useful in the treatment of cancer (both solid tumors and hematological malignancies), autoimmune diseases (e.g., rheumatoid arthritis, diabetes mellitus type 1 and multiple sclerosis), and other conditions such as Acquired Immunodeficiency Syndrome (AIDS), graft versus host disease (GVHD), vascular restenosis, and rejection of organ transplants (Nitetta, et al. 1993, Immunology Today 14:252-259; Biro et al, 1992, Circ. Res. 71:640-5; and Wawrzynczak and Derbyshire, 1992, Immunology Today 13:381-383).
  • cancer both solid tumors and hematological malignancies
  • autoimmune diseases e.g., rheumatoid arthritis, diabetes mellitus type 1 and multiple sclerosis
  • AIDS Acquired Immunodeficiency Syndrome
  • GVHD graft versus host disease
  • Targeting molecules utilized to convey various toxins include monoclonal antibodies and antibody fragments, growth factors (e.g., epidermal growth factor), cytokines (e.g., interleukin-2), and plant lectins.
  • growth factors e.g., epidermal growth factor
  • cytokines e.g., interleukin-2
  • plant lectins e.g., plant lectins.
  • the principal toxins (or their fragments) used currently are bacterial or plant in origin and include, but are not limited to, ricin, Diphtheria toxin and Pseudomonas exotoxin A (Nitetta et al, Immunology Today 14: 252-259; and Wawrzynczak and Derbysliire, 1992, Immunology Today 13: 381-383).
  • Ribosome-inactivating proteins are advantageous because many of them are single-chain, low molecular weight proteins (Wawrzynczak, 1991, Br. J. Cancer 64: 624-630; Francisco et al, 1997, J. Biol. Chem. 39:24165-24169).
  • a general method of preparation of toxin conjugates may involve use of thiol-crosslinking reagents such as the heterobifunctional cross-linking reagent ⁇ -succinimidyl 3-(2-pyridyldithio)propionate (SPDP), which attack the primary amino groups on the second protein and by disulfide exchange, attach the toxin to the second protein (e.g. , a targeting protein such as an antibody or growth factor).
  • the toxin is in the form of an immunotoxin comprising an antibody with specificity for a tumor- or disease-cell related cell surface receptor or antigen.
  • the immunotoxin is a single-chain immunotoxin ("SOT"), which comprises the Fv portion of an internalizing mAb linked to a truncated toxin that works inside the cell to stop protein synthesis.
  • SOT single-chain immunotoxin
  • the toxin is in the form of a fusion protein in which the toxin is fused to a ligand such as a growth factor or other signaling molecule, e.g. , a cytokine, that targets the toxin to tumor or disease cells that express a receptor for the ligand molecule.
  • Toxins suitable for use as immunogenic molecules according to the methods of the invention include molecules comprising plant-, fungus-, or bacteria-derived toxins, such as, for example, abrin, ricin A, Pseudomon ⁇ s exotoxin, Diphtheria toxin, Clostridium haratii type F-like toxin, Clostridium butyricum type E-like toxin, Staphylococcus enterotoxin A, botulinum toxin, tetanus toxin, modeccin, bungarotoxin, shigatoxin, cholera toxin, bryodin, saporin or gelonin.
  • the immunogenic molecule comprises
  • the Pseudomonas exotoxin is used as a genetically modified form termed PE40, which is a truncated form of the toxin in which the cell binding domain is deleted (see, Kondo et al, 1988, J. Biol. Chem. 263 :9470-9475).
  • the Pseudomonas exotoxin is PE38, another truncated form of the toxin in which the cell binding domain is deleted (see, Brinkmann et al, 1991, Proc Natl Acad Sci USA 88:8616-20). Because these forms of the exotoxin lacks a cell binding domain, they have to be administered covalently linked to an internalizing molecule such as a an internalizing monoclonal antibody.
  • the immunogenic molecule comprises ricin A
  • the molecule can be glycosylated (for example by expression in a eukaryotic cell) or deglycosylated (for example by expression in a bacterial cell).
  • the immunogenic molecule is deglycosylated ricin A due to its potency and lengthy half-life.
  • the immunogenic molecule is a monoclonal antibody-targeted toxin, more preferably a SCIT.
  • SCIT monoclonal antibody-targeted toxin
  • the immunotoxin is BR96 sFv-PE40, a single chain immunotoxin whose antibody portion recognizes the Le y antigen present on a number of carcinomas and whose toxin portion is a 40 kD form of Pseudomonas toxin lacking its cell- binding domain (PE40).
  • the immunotoxin is K305Fab-SEA(D227A), an immunotoxin comprising the Fab portion of K305, an antibody against the high-molecular- weight melanoma-associated antigen, and a mutant form of the superantigen staphylococcal enterotoxin A (Tordsson et al, 2000, Cancer Immunol. Immunother. 48:691-702).
  • the immunotoxin is C242Fab-SEA, an immunotoxin comprising the Fab portion of C242, a monoclonal antibody immunoreactive with human colon carcinomas, and the superantigen staphylococcal enterotoxin A (Dohlsten et al, 1995, Cancer Immunol. Immunother. 41 :162-68).
  • the immunotoxin comprises an antibody selected from MOC31 (an antibody against epithelial glycoprotein 2), BM7 (an antibody against MUC-1 mucin) and 425.3 (an antibody against the epidermal growth factor receptor), all of which are immunoreactive with human breast cancer cells, conjugated to Pseudomonas exotoxin (Engebraaten et al. , 2000, Int. J. Cancer 88:970-76).
  • MOC31 an antibody against epithelial glycoprotein 2
  • BM7 an antibody against MUC-1 mucin
  • 425.3 an antibody against the epidermal growth factor receptor
  • the immunotoxin is LMB-2, which comprises an antibody to the IL-2 receptor alpha subunit fused to PE38 (Onda et al, 2000, J. Immunol. 165:7150-561
  • the immunotoxin is Kl-LysPE38QQR, which is a chemical conjugate between Kl , a monoclonal antibody which recognizes mesothelin, a cell surface antigen that is overexpressed in epithelial ovarian cancer cells and in malignant mesotheliomas, and a form of PE38 with altered chemical conjugation properties (Hassan et al, 2000, J. Immunother. 23:473-79).
  • the immunotoxin is RFB4 (dsFv)-PE38(BL22), which comprises an Fv fragment of the anti-CD22 antibody RFB4, fused to PE38 (Kreitman et al, 2000, Clin. Cancer Res. 6(4): 1476-87).
  • RFB4 (dsFv)-PE38 recognizes CD22- expressing cells, including B cell malignancies.
  • the immunotoxin is MRl(Fv)-PE38 (Beers et al, 2000, Clin. Cane. Res. 6:2835-43); DT390-scFvUCHTl (an anti T-cell immunotoxin comprising a Diphtheria toxin fragment and an anti-CD30 antibody; Liu et al. , 2000,
  • Ki-4(scFv)-ETA' an immunotoxin with activity against Hodgkin's disease cells comprising a Pseudomonas exotoxin fragment and an anti-CD30 antibody; Barth et al, 2000, Blood 95:3909-14); RFT5(scFv)-ETA' (an immunotoxin with activity against Hodgkin's disease cells comprising an anti-CD25 antibody and a Pseudomonas exotoxin fragment; Barth et al, 2000, Int. J.
  • the toxin to which prevention of an immune response is desired is a non-monoclonal antibody targeted toxin.
  • exemplary non- monoclonal antibody targeted toxins are provided below.
  • the non-monoclonal antibody targeted toxin is denileukin diftitox, which is sold by Ligand Pharmaceuticals, Inc. under the trademark ONTAK®.
  • Denileukin diftitox is a single chain fusion protein composed of IL-2 and a truncated form of the bacterial protein toxin from Diphtheria. More specifically, denileukin diftitox is a recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for Diphtheria toxin fragments A and B (Met 1-Thr 387 )-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133 ), and is produced in an E.
  • the fusion protein designed to direct the cytocidal action of Diphtheria toxin to cells which express the IL-2 receptor.
  • the human IL-2 receptor exists in three forms, low (CD25), intermediate (CD122/CD132) and high (CD25/CD122/CD132) affinity.
  • the high affinity form of the IL-2 receptor is usually found only on activated T-cells, activated B- cells and activated macrophages. Malignant cells expressing one or more of the subunits of the IL-2 receptor are found in certain leukemias and lymphomas including cutaneous T-cell lymphoma.
  • non-monoclonal antibody targeted toxins are known to those of skill in the art and can be used in accordance with the disclosed methods.
  • Exemplary non- monoclonal antibody targeted toxins include IL13-PE38QQR (a cytotoxin against interleukin-13 receptor-expressing cells, such as Kaposi's sarcoma cells, comprising interleukin-13 and a Pseudomonas exotoxin fragment; Husain and Puri, 2000, Blood 95:3506-13); GnRH-PAP (a cytotoxin against gynecologic tumors comprising GnRH (gonadotrophin releasing hormone) and PAP, pokeweed antiviral protein, a ribosome inactivating protein); ATF-PE38 (comprising a urokinase fragment and PE38, with specificity to cells that express the urokinase plasminogen activator receptor; Rajagopal and Kreitman, 2000, J.
  • Biol. Chem. 275:7566-731 and CD30L-ETA' (comprising CD30 ligand and a fragment of Pseudomonas exotoxin; the CD30 ligand directs the toxin to the CD30- expressing Hodgkin's disease cells; Barth et al, 1999, Cytokines Cell Mol. Ther. 5:69-78).
  • the present invention provides methods for reduction or prevention of an immune response to, inter alia, an enzyme in a patient by administering to the patient an anti-CD20 monoclonal antibody in an amount sufficient to deplete the patient's circulating B-cells prior to, concurrently with or after the administration of the enzyme to the patient.
  • the enzyme is preferably a pro-drug converting enzyme (as described in Section 5.5.1 infra) or another enzyme administered for therapeutic purposes.
  • the enzyme can be a DNAse I with DNA degrading properties, targeted to a tumor cell (for example by means of an antibody against a tumor cell antigen), and whose delivery to a tumor cell is cytotoxic to the tumor cell (see, e.g., Linardou et al, 2000, Int. J. Cancer 86:561-69).
  • the immunogenic molecule comprises a pro-drag converting enzyme.
  • Drugs that normally have considerable toxicity to normal tissues can be administered as inactive pro-drugs and converted to their cytotoxic form by the enzyme that has been localized to the tumor microenvironment by a targeting molecule such as an antibody.
  • a targeting molecule such as an antibody.
  • This approach results in enzymatic conversion of the inactive pro-drag to the active drug specifically in tumor tissue, thus reducing exposure of normal tissue to the drug while maximizing concentrations in tumor tissue.
  • the pro-drug converting enzyme can be expressed as a fusion protein with or conjugated to an antibody to target the pro-drag converting enzyme to a specific cell type.
  • the pro-drug converting enzyme then cleaves nontoxic pro-drugs and release chemotherapeutically active drugs at a tumor site to which it has been targeted by the antibody.
  • Monoclonal antibodies that remain at the cell surface are preferred fusion partners for pro-drug converting enzymes.
  • the pro-drug converting enzyme can be expressed as a fusion protein with or conjugated to a growth factor or other signaling molecule, such as a cytokine, to target the enzyme to cells that express a receptor for the growth factor or signaling molecule.
  • the immunogenic molecule comprises a pro-drug converting enzyme
  • the immunogenic molecule is administered prior to the pro-drag, which is then activated at the site to which the pro-drug converting enzyme has been targeted.
  • Regimens of administration of pro-drag converting enzymes and pro- drags are known to those of skill in the art.
  • pro-drug converting enzymes are carboxypeptidase G2, beta- glucuronidase, penicillin-N-amidase, penicillin-G-amidase, ⁇ -lactamase, ⁇ -glucosidase, nitroreductase and carboxypeptidase A.
  • the immunogenic molecule comprises the cloned binding region (sFv) of the L49 monoclonal antibody that binds to the p97 antigen (a human melanoma-associated antigen) and the highly specific enzyme ⁇ -lactamase.
  • the p97 antigen is also expressed in many ovarian, breast and lung cancers.
  • the L49 monoclonal antibody binds to its antigen, the mAb does not penetrate inside the cell, rather it sits on the cell surface.
  • L49 is retained on the cell surface leaving the fused enzymatic portion exposed and available to activate pro-drug substrates.
  • the L49 sFv- ⁇ -lactamase fusion protein is administered with a cephalosporin derivative of the clinically approved drag melphalan, an alkylating agent.
  • a cephalosporin derivative of the clinically approved drag melphalan an alkylating agent.
  • the immunogenic molecule is a fusion between the single-chain anti-carcinoma antibody 323/A3 and beta-glucuronidase (Haisma et al, 1998, Cancer Immunol Immunother 45(5):266-72), which catalyzes the conversion of the pro-drug ⁇ -[4-doxorubicin- ⁇ -carbonyl(oxymethyl)phenyl]-O-beta-glucuronyl carbamate to the cytotoxic drug doxorubicin.
  • an anti-CD20 antibody is administered to deplete B-cells in order to prevent an immune response to a protein expressed by a gene therapy vector.
  • Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible nucleic acid.
  • the nucleic acid is often a replicable viral genome engineered to express a heterologous protein that mediates a therapeutic effect.
  • Gene therapy is often limited by the patient's immune response to viral vectors of gene therapy, such as adenovirus vectors (see, e.g., Yang et al, 1994, Proc. Natl. Acad. Sci. USA 91:4407-4411).
  • adenovirus harboring a factor IX for treatment of hemophilia
  • administration of an adenovirus harboring a factor IX results in only short term expression of the factor LX gene and re-administration of the vector is prevented because of neutralizing antibodies to the adenovirus.
  • administration of the same gene therapy vector to nude mice results in long term expression of the factor IX (Dai et al, 1995, Proc. Natl. Acad. Sci U.S.A. 92:1401-1405).
  • suppression of the immune response to the adenovirus vector would be expected to prolong the usefulness of gene therapy.
  • Immune responses against both the native proteins of the gene therapy vector and the heterologous, therapeutic protein expressed by the vector can both be prevented by the disclosed methods.
  • the anti-CD20 antibody can be used in conjunction with any gene therapy vector available in the art. Exemplary vectors and methods are described below. For general reviews of the methods of gene therapy, see, Goldspiel et al. ,
  • Delivery of a gene therapy vector into a subject may be either direct, in which case the subject is directly exposed to the nucleic acid or nucleic acid- carrying vector, or indirect, in which case, cells are first transformed with the nucleic acids in vitro, then transplanted into the subject. These two approaches are known, respectively, as in vivo or ex vivo gene therapy.
  • the nucleic acid sequences are directly administered in vivo, where it is expressed to produce the encoded product. This can be accomplished by any of numerous methods known in the art, for example by constructing them as part of an appropriate nucleic acid expression vector and administering the vector so that the nucleic acid sequences become intracellular.
  • Gene therapy vectors can be administered by infection using defective or attenuated retrovirals or other viral vectors (see, e.g., U.S. Patent No.
  • nucleic acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation.
  • the nucleic acid can be targeted in vivo for cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT Publications WO 92/06 180; WO 92/22635; W092/20316; W093/14188, and WO 93/20221).
  • the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression by homologous recombination (Koller and Smithies, 1989, Proc. Natl. Acad. Sci. USA 86:8932-8935; Zijlstra et al, 1989, Nature 342:435-4381
  • viral vectors that contain nucleic acid sequences encoding an antibody of the invention are used.
  • a retro viral vector can be used (see Miller et al, 1993, Mefh. Enzymol. 217:581-599). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the host cell DNA.
  • the nucleic acid sequences encoding the antibody to be used in gene therapy are cloned into one or more vectors, thereby facilitating delivery of the gene into a subject. More detail about retroviral vectors can be found in Boesen et al.
  • Another approach to gene therapy involves transferring a gene encoding a therapeutic protein to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection.
  • the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a subject.
  • the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell.
  • introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell mediated gene transfer, spheroplast fusion, etc.
  • Numerous techniques are known in the art for the introduction of foreign genes into cells (see, e.g., Loeffler and Behr, 1993, Meth. Enzymol. 217:599-618; Cohen et al, 1993, Meth. Enzymol.
  • the technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny.
  • Recombinant blood cells e.g., hematopoietic stem or progenitor cells
  • Recombinant blood cells are preferably administered intravenously.
  • the amount of cells envisioned for use depends on the desired effect, subject state, etc., and can be determined by one skilled in the art.
  • Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to fibroblasts; blood cells such as T lymphocytes, B lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g. , as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.
  • the cell used for gene therapy is autologous to the subject.
  • nucleic acid sequences encoding an antibody are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for therapeutic effect.
  • stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained in vitro can potentially be used in accordance with this embodiment of the present invention (see e.g. PCT Publication WO 94/08598; Stemple and Anderson, 1992, Cell 71:973-985; Rheinwald, 1980, Meth. Cell Bio. 21A:229; and Pittelkow and Scott, 1986, Mayo Clinic Proc. 61:771).
  • the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription.
  • the methods of the present invention can be used to reduce or prevent a humoral immune response to any therapeutic molecule that is immunogenic, provided that the therapeutic molecule is not a component of a tissue transplant.
  • therapeutic molecules that have immunogenic properties and with which the methods of the present invention can be practiced include recombinant GM-CSF (Wadhwa et al, 1999, Clin. Cancer Res. 5:1353-61) and recombinant thrombopoietin "TPO" (Wendling and Vainchenker, 1999, 5 Hematologie 5:289-94).
  • the invention provides methods of preventing a humoral immune response
  • prevention of a humoral immune response entails depletion of the patient's B-cells with an anti-CD20 antibody, which prolongs the half life of the immunogenic molecule in the patient's circulation and/or prevents neutralization of ⁇ the immunogenic molecule, thereby increasing the therapeutic efficacy of the immunogenic molecule.
  • the anti-CD20 antibody is substantially purified (e.g., substantially free from substances that limit its effect or produce undesired side-effects).
  • the subject is preferably an animal, including but not limited to animals such as cows, pigs,
  • CD20 antibody in accordance with the methods of the present invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis (see, e.g., Wu and Wu, 1987, J. Biol. Chem. 262:4429-4432).
  • Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral Q routes.
  • the anti-CD20 antibodies may be also administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents, including but not limited to an immunogenic molecule. Administration can be systemic or local. or in a specific embodiment, it may be desirable to administer the anti-CD20 antibody by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including a membrane, such as a sialastic membrane, or a fiber.
  • the anti-CD20 antibody can be delivered in a vesicle, in particular a liposome (see Langer, 1990, Science 249:1527-1533; Treat et al,
  • the anti-CD20 antibody can be delivered in a controlled release system.
  • a pump may be used (see Langer, supra; Sefton, 1989, CRC Crit. Ref. Biomed. Eng. 14:201; Buchwald et al, 1980, Surgery 88:507; Saudek et al, 1989, N. Engl. J. Med. 321:574).
  • polymeric materials can be used (see Medical Applications of Controlled Release, 1974, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida; Controlled Drug Bioavailability, Drag
  • compositions comprising an amount of anti-CD20 antibody effective to deplete a patient's B-cells further comprise a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable means approved by a regulatory agency of the Federal or a state government or listed in the U.S.
  • carrier refers to a diluent, adjuvant, excipient, or vehicle with which the anti-CD20 antibody is administered.
  • Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
  • Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
  • the composition if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like.
  • the composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides.
  • the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate) lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate).
  • binding agents e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
  • fillers e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate
  • lubricants e.g., magnesium stearate, talc or silica
  • disintegrants e.g., potato starch
  • Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicles before use.
  • Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid).
  • suspending agents e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats
  • emulsifying agents e.g., lecithin or acacia
  • non-aqueous vehicles e.g., almond oil, oily esters, ethy
  • compositions may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.
  • suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences” by E.W. Martin.
  • Such compositions will contain a therapeutically effective amount of the anti-CD20 antibody, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient.
  • the formulation should suit the mode of administration.
  • Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
  • compositions may take the form of tablets or lozenges formulated in conventional manner.
  • the anti-CD20 antibodies are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas
  • the anti-CD20 antibodies may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers, with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. , sterile pyrogen-free water, before use.
  • the anti-CD20 antibodies may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
  • the anti-CD20 antibodies may also be formulated as a depot preparation.
  • Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • the proteins may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • the pharmaceutical composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings.
  • compositions for intravenous administration are solutions in sterile isotonic aqueous buffer.
  • the pharmaceutical composition may also include a solubilizing agent and a local anesthetic such as lidocaine to ease pain at the site of the injection.
  • the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampule or sachette indicating the quantity of active agent, i.e., the anti-CD20 antibody.
  • the pharmaceutical of the invention can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline.
  • an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.
  • the anti-CD20 antibody compositions may, if desired, be presented in a pack or dispenser device that may contain one or more unit dosage forms containing the active ingredient.
  • the pack may for example comprise metal or plastic foil, such as a blister pack.
  • the pack or dispenser device may be accompanied by instructions for administration preferably for administration to a human.
  • the method of administration of the immunogenic molecule will depend on the type of immunogenic molecule being administered. Methods of administering immunogenic molecules that are components of gene therapy vectors are described in Section 5.6, supra.
  • immunogenic molecules that are administered as proteins such as, but not limited to, immunotoxins or fusion proteins comprising antigenic proteins such as pro-drag converting enzymes
  • compositions and methods of administration are generally similar to those described for the anti-CD20 antibodies and will be readily apparent to those of skill in the art.
  • the amount of the anti-CD20 antibody which will be effective to deplete a patient's B-cells in accordance with the methods of the present invention can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the timing of administration of the anti- CD20 antibody relative to administration of the immunogenic molecule, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from animal model test systems.
  • the amount of anti-CD20 antibody administered is sufficient to deplete the patient's circulating B-cells by at least 25%, more preferably by at least 35%, yet more preferably by at least 50%, and most preferably by at least 60%. In other embodiments, the amount of anti-CD20 antibody administered is sufficient to deplete the patient's circulating B-cells by at least 75%, at least 85%, or at least 90%. Toxicity and therapeutic efficacy of a particular anti-CD20 antibody in conjunction with a given immunogenic molecule can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD 50 (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population).
  • the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD 50 /ED 50 .
  • the data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans.
  • the dosage of particular combinations of immunogenic molecules and anti-CD20 antibodies lies preferably within a range of circulating concentrations that include the ED 50 with little or no toxicity.
  • the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
  • the therapeutically effective dose can be estimated initially from cell culture assays.
  • a dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC 50 (i.e., the concentration of the test compound that achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.
  • the dosage of an anti-CD20 antibody administered to deplete a patient's B-cells is typically 0.1 mg/kg to 100 mg/kg of the patient's body weight.
  • the dosage administered to a patient is between 0.1 mg/kg and 20 mg/kg of the patient's body weight, more preferably 1 mg/kg to 10 mg/kg of the patient's body weight.
  • the dosage of the anti-CD20 antibody is 50 mg/m 2 to 1000 mg/m 2 , more preferably 100 mg/m 2 to 750 mg/m 2 , more preferably 200 mg/m 2 to 500 mg/m 2 , and yet more preferably 300 mg/m 2 to 400 mg/m 2 of a patient's body surface area.
  • the more 'human' an anti-CD20 antibody is, the longer its half-life within the human body, and the lower the dosages that be required to deplete the patient's B-cells.
  • B-cells in a patient's sample can be detected and counted by measuring the presence of surface transmembrane immunoglobulin.
  • Anti- immunoglobulin antisera against different classes of immunoglobulins can be labeled with a fluorescent label and the number of B-cells in the sample measured by contacting the sample with the mixture of fluorescently labeled antisera and the cells with surface fluorescence counted in the sample.
  • B-cells can be quantified to determine the extent of their depletion by flow cytometry.
  • peripheral blood mononuclear cells PBMC
  • B cell markers such as CD20, CD19 and/or CD33
  • fluorochrome conjugated to fluorochrome
  • the cell mixture is then washed by one or more centrifugation and resuspension steps.
  • the resulting cell population is analyzed by flow cytometry to determine the number of B-cells present in the sample, for example on an EPICS C (Coulter Electronics, Hileah, Fla.).
  • EPICS C Coulter Electronics, Hileah, Fla.
  • an anti-CD20 antibody is administered to a patient in order to deplete a patient's B-cells so that a humoral immune response is not mounted against an immunogenic molecule that is administered to the patient for therapy.
  • the anti-CD20 antibody is administered prior to administration of the immunogenic molecule, so that the patient's B-cells are depleted prior to administration of the immunogenic molecule, but not so long prior to administration of the immunogenic molecule that the patient's B-cells regenerate prior to the administration of the immunogenic molecule.
  • the immunogenic molecule is administered within about five hours, within about 12 hours, within about one day, within about two days, within about three days, within about five days, within about a week, within about ten days, within about two weeks or within about three weeks of administration of the anti-CD20 antibody.
  • the anti-CD20 antibody is administered concurrently with administration of the immunogenic molecule. In yet another embodiment of the invention, the anti-CD20 antibody is administered following administration of the immunogenic molecule. In a preferred mode of the embodiment, the anti-CD20 antibody is administered no later than one week after the administration of the immunogenic molecule, more preferably no later than 3 days after the administration of the immunogenic molecule, more preferably no later than 1 day after the administration of the immunogenic molecule, and most preferably no later than 12 hours after the administration of the immunogenic molecule.
  • a course of anti-CD20 antibody comprising more than one dose of the antibody is administered to a patient.
  • the course is initiated and completed prior to administration of an immunogenic molecule to the patient.
  • the course is initiated prior to the first administration of the immunogenic molecule to the patient and completed concurrently with the first administration of the immunogenic molecule to the patient.
  • the course is initiated prior to the first administration of the immunogenic molecule to the patient and completed (i.e., the last dose is administered) concurrently with the first administration of the immunogenic molecule to the patient.
  • the course is initiated prior to the first administration of the immunogenic molecule to the patient and completed (i.e., the last dose is administered) concurrently with the administration of the immunogenic molecule to the patient. In yet other embodiments, the course is initiated concurrently or following the first administration of the immunogenic molecule to the patient and completed after the first administration of the immunogenic molecule to the patient.
  • a course of anti-CD20 antibody comprises two administrations of the antibody. In another embodiment, a course of anti-CD20 antibody comprises three administrations of the antibody. In yet other embodiments, a course of anti- CD20 antibody comprises four, five or six administrations of the antibody. The administrations can be separated by an average of about a week, about five days, about four days, about three days or about two days.
  • the invention also provides a pharmaceutical pack or kit comprising one or more containers filled with an anti-CD20 antibody and an immunogenic molecule, and optionally one or more pharmaceutical carriers.
  • the immunogenic molecule is BR96 sFv-PE40.
  • the immunogenic molecule is denileukin diftitox (ONTAK®).
  • Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
  • BR96 sFv-PE40 is a single chain immunotoxin comprised of the variable region of the monoclonal antibody BR96, which recognizes the Le y antigen present on a number of carcinomas and a toxin portion that is a 40 kD form of Pseudomonas exotoxin lacking its cell-binding domain.
  • BR96 sFv-PE40 has antitumor activity in vivo (see, e.g., Friedman et al, 1993, J. Immunol.l50:3054-3061), but its efficacy in humans is potentially limited by the immune response mounted against the toxin component of the molecule.
  • HATA human anti-toxin antibodies
  • Immulon II ELISA plates were coated with 100 ⁇ l Capture Reagent (2 ⁇ g/mL of BR96 sFv-PE40 in PBS/0.1% NaN 3 ) per well. The plates were covered with plastic sealers and incubated overnight at 4°C. The plates were washed with PBST (PBS (pH 7.4, 10 mM phosphate, 2.7 mM KC1, and 137 mM NaCl)/0.05% Tween-20/0.1% NaN 3 ). 200 ⁇ L Blocking Buffer (1.0% gelatin/3.0% powdered milk in 100 mL PBS) was added and the plates covered and incubated for 1-2 hours at 37 °C. The plates were then washed 3 times with PBST.
  • PBST PBS (pH 7.4, 10 mM phosphate, 2.7 mM KC1, and 137 mM NaCl)/0.05% Tween-20/0.1% NaN 3 ).
  • Blocking Buffer (1.0% gelatin
  • Reference standard (BR96 sFv-PE40 hyperimmunized cynomolgus monkey sera) and various dilutions of the patients' sera were added to the plates, the plates were covered and incubated for 1-2 hours at 37 °C. The plates were washed 4 times with PBST then the secondary antibody cocktail (1 :5000/l :2500/l :2500 dilution in binding buffer of goat anti-human IgG/IgM/IgA, respectively) was added. The plates were covered and incubated for 1-2 hours at 37 °C. Following incubation, the plates were washed 5 times with PBST.
  • Detection reagent (1 mg/niL PNPP (4-Nitrophenyl phosphate) in DEA (diethanolamine) buffer) was added to the plates and the plates covered and incubated for 25 minutes at 25 °C, after which time 50 ⁇ L 3N NaOH stop reagent was added to the plates.
  • the optical density (OD) of the ELISA signal was measured at 450 nm and the greatest serum dilution that gave rise to a detectable signal, an indirect measure of HATA concentration in the serum, was determined. Conversion to seropositivity is defined as an OD of three times the standard deviation (SD) above background OD. A titer of 1:7290 is the cut off for serologic significance.
  • HATA human anti-toxin antibody
  • PE40 was determined. Human tumor cell lines were exposed to serum from patients to whom BR96 sFv-PE40 had been administered, and the cytotoxic effect of the serum
  • L2987 cells were cultured as monolayers at 37°C/5% CO 2 in RPMI 1640 supplemented with 10% FBS and 50 U/ml penicillin/streptomycin. Tumor cells were plated
  • FIG. 1 shows the percentage inhibition protein synthesis elicited by serum obtained from (i) patient 1 -003 at day 4 of treatment with BR96 sFv-PE40, when the HATA titer was
  • PK pharmacokinetics
  • All patients in the PK cohort received a BR96 sFv-PE40 dose of 0.641 mg/m 2 .
  • Sampling time points were immediately prior to administration of BR96 sFv-PE40, and, then as indicated following administration of BR96 sFv-PE40, at post infusion 5, 15, 30, 60, 90, 180 and/or 240 5 minutes.
  • the ELISA experiments were conducted as follows. Anti-PE monoclonal antibody EXA2-1H8 was diluted in sterile PBS (10 mM phosphate, 2.7 mM KC1, and 137 mM NaCl at pH 7.4) to yield a 4 ⁇ g/mL working solution (Siegall et al. , 1994, J. Immunol. 152(512377-84). The ELISA plates were prepared plates by adding 100 ⁇ L of the working 0 solution of EXA2-1H8 to each well. The assay plates were then covered with a plate sealer and stored at 4°C for 16-48 hours. The coating solution was manually flicked from the plates.
  • the mean peak plasma concentration was 413ng/mL ⁇ 101 and the calculated mean plasma half life (VT was 2.5 hours.
  • the corresponding HATA titers are listed and demonstrate a clear relationship between increasing titers and more rapid clearance of the drag (BR96 sFv-PE40) from the circulation (Table 2).
  • the anti-CD20 antibody C2B8 (in the form of the drug Rituxan®) was incorporated into the BR96 sFv-PE40 phase I study to evaluate its ability to limit the BR96 sFv-PE40-induced immune response.
  • a cohort of patients was treated with a full course of C2B8 (4 doses of C2B8 at a dose of 375 mg/m 2 over 2 weeks) prior to receiving the first dose of BR96 sFv-PE40.
  • peripheral B cell depletion Prior to receiving the first dose of BR96 sFv-PE40, peripheral B cell depletion was documented.
  • lOO ⁇ l of the patient's blood sample was mixed 5 ⁇ l of each of three antibodies, anti-CD 19 (a B cell marker), anti-CD20 (another B cell marker) and anti-CD45 (a lymphocyte marker).
  • Each of the antibodies was conjugated to a different fluorescent signal.
  • the antibody- sample mixture was incubated for 15 minutes in the dark. Following the 15 -minute incubation period, 2 ml of Saponin-Formalin Solution (a 1 :5 dilution of a solution containing 100ml of 10% formalin, 100 ml lOx PBS, 700 mg of Saponin and 2ml of 5% sodium azide) was added to the tubes.
  • the Saponin-Formalin Solution was added to the blood sample, the resulting mixture was vortexed and incubated for 10 minutes in the dark. Addition of this solution resulted in the simultaneous lysis of red blood cells and partial formation of white cells.
  • the cells were pelleted by a 5 minutes centrifugation at 1500 rpm for 5 minutes, and the supernatant aspirated.
  • the cells were resuspended in a lx PBS wash solution, and centrifuged as before, and the supernatant aspirated.
  • the resulting pellet was resuspended in 0.2 ml of lx PBS and subjected to flow cytometric analysis on a FACScan/FACSort instrument.
  • the percentage of B cells in a sample was a total of anti- CD 19 and anti-CD20-derived fluorescence over total fluorescence.
  • HATA anti-toxin antibodies

Abstract

La présente invention concerne des méthodes destinées à réduire une réponse immune humorale chez un patient, ou à empêcher ce dernier de développer des anticorps qui neutralisent ou limitent l'efficacité de molécules thérapeutiques. Ces méthodes sont fondées sur l'utilisation d'anticorps anti-CD20 visant à épuiser les cellules B de sécrétion d'anticorps chez un patient. On décrit un dosage et des régimes thérapeutiques appropriés. L'invention concerne en outre des trousses contenant des réactifs destinés à la mise en oeuvre des méthodes de l'invention.
PCT/US2002/014600 2001-05-10 2002-05-10 Immunosuppression de la reponse immune humorale par des anticorps anti-cd20 WO2003061694A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29031901P 2001-05-10 2001-05-10
US60/290,319 2001-05-10

Publications (1)

Publication Number Publication Date
WO2003061694A1 true WO2003061694A1 (fr) 2003-07-31

Family

ID=27613152

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/014600 WO2003061694A1 (fr) 2001-05-10 2002-05-10 Immunosuppression de la reponse immune humorale par des anticorps anti-cd20

Country Status (1)

Country Link
WO (1) WO2003061694A1 (fr)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016969A2 (fr) * 2003-08-14 2005-02-24 Merck Patent Gmbh Compositions de polypeptides de liaison a cd20
WO2005042028A2 (fr) * 2003-10-27 2005-05-12 Neopharm, Inc. Immunotoxine ou cytotoxine a conjugue il-13 et utilisations correspondantes
WO2006010360A2 (fr) * 2004-07-22 2006-02-02 Biotecon Therapeutics Gmbh Vehicule permettant d'obtenir des medicaments a biodisponibilite orale
EP2077281A1 (fr) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anticorps anti-CD20 ou fragments correspondants pour le traitement de syndrome de fatigue chronique
US7740847B2 (en) 2004-08-04 2010-06-22 Applied Molecular Evolution, Inc. Variant Fc regions
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
US7799900B2 (en) 2002-12-16 2010-09-21 Genentech, Inc. Immunoglobulin variants and uses thereof
EP2233149A1 (fr) 2007-10-16 2010-09-29 ZymoGenetics, Inc. Combinaison de l'inhibition du BLYS et d'un agent anti-CD20 pour le traitement des maladies auto-immunes
EP2272868A2 (fr) 2003-06-05 2011-01-12 Genentech, Inc. Thérapie de combinaison pour des désordres de cellules B
WO2011019619A1 (fr) 2009-08-11 2011-02-17 Genentech, Inc. Production de protéines dans des milieux de culture cellulaire sans glutamine
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
WO2011100403A1 (fr) 2010-02-10 2011-08-18 Immunogen, Inc Anticorps anti-cd20 et utilisations de ceux-ci
EP2586788A1 (fr) 2007-07-09 2013-05-01 Genentech, Inc. Prévention de la réduction des liaisons de disulfure pendant la production recombinante de polypeptides
US8883980B2 (en) 2003-11-05 2014-11-11 Roche Glycart Ag Antigen binding molecules with increased Fc receptor binding affinity and effector function
US9416187B2 (en) 2003-05-09 2016-08-16 Duke University CD-20 specific antibodies and methods of employing same
EP3095463A2 (fr) 2008-09-16 2016-11-23 F. Hoffmann-La Roche AG Procédés pour traiter la sclérose en plaques progressive
WO2016196344A1 (fr) 2015-05-30 2016-12-08 Molecular Templates, Inc. Supports de sous-unité a de toxine de shiga, déimmunisés, et molécules de ciblage de cellule les comprenant
EP3130349A1 (fr) 2004-06-04 2017-02-15 Genentech, Inc. Methode de traitement de la sclerose en plaques
WO2017055542A1 (fr) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anticorps de récepteur de la transferrine humaine/anti-humaine cd20 bispécifique et leurs procédés d'utilisation
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
US10450379B2 (en) 2005-11-15 2019-10-22 Genetech, Inc. Method for treating joint damage
US10941205B2 (en) 2015-10-02 2021-03-09 Hoffmann-La Roche Inc. Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use
WO2022018726A1 (fr) * 2020-07-20 2022-01-27 Neotx Therapeutics Ltd. Conjugué de superantigène destiné à être utilisé dans des procédés et des compositions pour le traitement du cancer
US11584793B2 (en) 2015-06-24 2023-02-21 Hoffmann-La Roche Inc. Anti-transferrin receptor antibodies with tailored affinity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GONZALES-STAWINSKI ET AL.: "Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8 Rituximab)", CLINICAL IMMUNOLOGY, vol. 98, no. 2, February 2001 (2001-02-01), pages 175 - 179, XP002966170 *
PAI ET AL.: "Immunotoxin therapy for cancer", JAMA, vol. 269, no. 1, 6 January 1993 (1993-01-06), pages 78 - 81, XP002966171 *

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799900B2 (en) 2002-12-16 2010-09-21 Genentech, Inc. Immunoglobulin variants and uses thereof
US9416187B2 (en) 2003-05-09 2016-08-16 Duke University CD-20 specific antibodies and methods of employing same
EP2272868A2 (fr) 2003-06-05 2011-01-12 Genentech, Inc. Thérapie de combinaison pour des désordres de cellules B
AU2004264372B2 (en) * 2003-08-14 2010-07-29 Merck Patent Gmbh CD20-binding polypeptide compositions
WO2005016969A3 (fr) * 2003-08-14 2005-04-21 Merck Patent Gmbh Compositions de polypeptides de liaison a cd20
CN1835977A (zh) * 2003-08-14 2006-09-20 默克专利有限公司 Cd20－结合多肽组合物
WO2005016969A2 (fr) * 2003-08-14 2005-02-24 Merck Patent Gmbh Compositions de polypeptides de liaison a cd20
CN1835977B (zh) * 2003-08-14 2012-10-31 默克专利有限公司 Cd20-结合多肽组合物
WO2005042028A2 (fr) * 2003-10-27 2005-05-12 Neopharm, Inc. Immunotoxine ou cytotoxine a conjugue il-13 et utilisations correspondantes
WO2005042028A3 (fr) * 2003-10-27 2006-10-05 Neopharm Inc Immunotoxine ou cytotoxine a conjugue il-13 et utilisations correspondantes
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
US8883980B2 (en) 2003-11-05 2014-11-11 Roche Glycart Ag Antigen binding molecules with increased Fc receptor binding affinity and effector function
EP3130349A1 (fr) 2004-06-04 2017-02-15 Genentech, Inc. Methode de traitement de la sclerose en plaques
WO2006010360A2 (fr) * 2004-07-22 2006-02-02 Biotecon Therapeutics Gmbh Vehicule permettant d'obtenir des medicaments a biodisponibilite orale
WO2006010360A3 (fr) * 2004-07-22 2007-12-27 Biotecon Therapeutics Gmbh Vehicule permettant d'obtenir des medicaments a biodisponibilite orale
US7740847B2 (en) 2004-08-04 2010-06-22 Applied Molecular Evolution, Inc. Variant Fc regions
US10654940B2 (en) 2005-11-15 2020-05-19 Genentech, Inc. Method for treating joint damage
US10450379B2 (en) 2005-11-15 2019-10-22 Genetech, Inc. Method for treating joint damage
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
EP3327026A1 (fr) 2007-07-09 2018-05-30 Genentech, Inc. Prévention de la réduction des liaisons de disulfure pendant la production recombinante de polypeptides
EP4245766A2 (fr) 2007-07-09 2023-09-20 Genentech, Inc. Prévention de la réduction de liaisons disulfures pendant la production recombinante de polypeptides
EP4335863A2 (fr) 2007-07-09 2024-03-13 Genentech, Inc. Prévention de la réduction de liaisons disulfures pendant la production recombinante de polypeptides
EP2586788A1 (fr) 2007-07-09 2013-05-01 Genentech, Inc. Prévention de la réduction des liaisons de disulfure pendant la production recombinante de polypeptides
EP4219522A2 (fr) 2007-07-09 2023-08-02 Genentech, Inc. Prévention de la réduction de liaisons disulfures pendant la production recombinante de polypeptides
EP2233149A1 (fr) 2007-10-16 2010-09-29 ZymoGenetics, Inc. Combinaison de l'inhibition du BLYS et d'un agent anti-CD20 pour le traitement des maladies auto-immunes
EP2077281A1 (fr) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anticorps anti-CD20 ou fragments correspondants pour le traitement de syndrome de fatigue chronique
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US9994642B2 (en) 2008-09-16 2018-06-12 Genentech, Inc. Methods for treating progressive multiple sclerosis
US9683047B2 (en) 2008-09-16 2017-06-20 Genentech, Inc. Methods for treating progressive multiple sclerosis
EP3747464A1 (fr) 2008-09-16 2020-12-09 F. Hoffmann-La Roche AG Procédés pour traiter la sclérose en plaques progressive avec un anticorps contre cd20
EP3095463A2 (fr) 2008-09-16 2016-11-23 F. Hoffmann-La Roche AG Procédés pour traiter la sclérose en plaques progressive
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
WO2011019619A1 (fr) 2009-08-11 2011-02-17 Genentech, Inc. Production de protéines dans des milieux de culture cellulaire sans glutamine
EP3760712A1 (fr) 2009-08-11 2021-01-06 F. Hoffmann-La Roche AG Production de protéines dans des milieux de culture cellulaire sans glutamine
WO2011100403A1 (fr) 2010-02-10 2011-08-18 Immunogen, Inc Anticorps anti-cd20 et utilisations de ceux-ci
EP3636660A1 (fr) 2015-05-30 2020-04-15 Molecular Templates, Inc. Échafaudages à sous-unités a de shiga-toxines désimmunisés et molécules de ciblage de cellules les comprenant
WO2016196344A1 (fr) 2015-05-30 2016-12-08 Molecular Templates, Inc. Supports de sous-unité a de toxine de shiga, déimmunisés, et molécules de ciblage de cellule les comprenant
EP3660035A1 (fr) 2015-05-30 2020-06-03 Molecular Templates, Inc. Supports de sous-unité a de toxine de shiga, déimmunisés, et molécules de ciblage de cellule les comprenant
US11584793B2 (en) 2015-06-24 2023-02-21 Hoffmann-La Roche Inc. Anti-transferrin receptor antibodies with tailored affinity
WO2017055542A1 (fr) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anticorps de récepteur de la transferrine humaine/anti-humaine cd20 bispécifique et leurs procédés d'utilisation
US11603411B2 (en) 2015-10-02 2023-03-14 Hoffmann-La Roche Inc. Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
US10941205B2 (en) 2015-10-02 2021-03-09 Hoffmann-La Roche Inc. Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use
WO2022018726A1 (fr) * 2020-07-20 2022-01-27 Neotx Therapeutics Ltd. Conjugué de superantigène destiné à être utilisé dans des procédés et des compositions pour le traitement du cancer

Similar Documents

Publication Publication Date Title
WO2003061694A1 (fr) Immunosuppression de la reponse immune humorale par des anticorps anti-cd20
US7090843B1 (en) Recombinant anti-CD30 antibodies and uses thereof
US20210236650A1 (en) Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
AU2002236518A1 (en) Recombinant anti-CD30 antibodies and uses thereof
US20080213289A1 (en) Recombinant anti-cd30 antibodies and uses thereof
US20080317747A1 (en) Recombinant anti-cd30 antibodies and uses thereof
US20210371541A1 (en) Conjugated antiboides against ly75 for the treatment of cancer
JP2017500028A (ja) 新規の抗ｄｐｅｐ３抗体および使用方法
TWI789379B (zh) 醫藥組合
KR20200143634A (ko) 탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자
JP2023548538A (ja) 併用療法
RU2478648C2 (ru) Антитело против удлиненного гликосфинголипида i типа, его производные и применение
US20230270877A1 (en) Combination Therapy
AU2007200173B2 (en) Recombinant anti-CD30 antibodies and uses thereof
CN116801871A (zh) 组合疗法
NZ718617B2 (en) Conjugated antibodies against ly75 for the treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP